Intervention Review

You have free access to this content

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

  1. Karen A Robinson1,*,
  2. Olaide A Odelola2,
  3. Ian J Saldanha3

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 22 MAY 2014

Assessed as up-to-date: 12 MAY 2014

DOI: 10.1002/14651858.CD007743.pub5


How to Cite

Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD007743. DOI: 10.1002/14651858.CD007743.pub5.

Author Information

  1. 1

    Johns Hopkins University, Department of Medicine, Baltimore, MD, USA

  2. 2

    Albert Einstein Medical Center, Department of Internal Medicine, Philedelphia, PA, USA

  3. 3

    Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD, USA

*Karen A Robinson, Department of Medicine, Johns Hopkins University, 1830 E. Monument St., Suite 8068, Baltimore, MD, 21287, USA. krobin@jhmi.edu.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 22 MAY 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Cohen 2005 {published and unpublished data}
  • Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of Synagis® (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. Poster session presented at the American Thoracic Society International Conference 2005 May 20-25; San Diego, USA. 2005.
  • Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of Synagis® (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract]. Proceedings of the American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA. 2005:A178.

Additional references

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
AAP 2009
Abman 1988
  • Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalization for respiratory distress of young infants with cystic fibrosis. Journal of Pediatrics 1988;113(5):826-30.
Armstrong 1998
Arnold 1999
  • Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV Database. Pediatric Investigators Collaborative Network on Infections in Canada. The Pediatric Infectious Disease Journal 1999;18(10):866-9.
Cane 2001
CFF 2009
  • Cystic Fibrosis Foundation. Newborn screening for cystic fibrosis. http://www.cff.org/GetInvolved/Advocate/NewbornScreening (accessed December 03, 2009).
Colasurdo 2006
Deeks 2011
  • Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Dupont 1990
Efthimiou 1984
  • Efthimiou J, Hodson ME, Taylor P, Taylor AG, Batten JC. Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis. Thorax 1984 Feb;39(2):150-4.
Feltes 2003
  • Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics 2003;143(4):532-40.
Fenton 2004
  • Fenton C, Scott LI, Plosker GL. Palivizumab: A review of its use as prophylaxis for serious respiratory syncytial virus infection. Pediatric Drugs 2004;6(3):177-97.
Giebels 2008
Glezen 1986
  • Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. American Journal of Diseases in Children 1986;140(6):543-6.
Henderson 2005
Hiatt 1999
  • Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103(3):619-26.
Higgins 2003
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
IMpact-RSV 1998
  • The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-7.
Khan 1995
  • Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995;151(4):1075-82.
Kirchner 1996
  • Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1996;154(5):1426-9.
Lau 2006
Leader 2002
McCormick 2007
Mejias 2004
  • Mejias A, Chavez-Bueno S, Rios AM, Saavedra-Lozano J, Aten MF, Hatfield J, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrobial Agents and Chemotherapy 2004;48(5):1811-22.
NHS 2009
  • National Health Service. Newborn Blood Spot screening across the UK . http://www.screening.nhs.uk/bloodspot-compare (accessed December 03, 2009).
Pedraz 2003
  • Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatric Infectious Disease Journal 2003;22(9):823-7.
Piedimonte 2004
Pohl 1992
  • Pohl C, Green M, Wald ER, Ledesma-Medina J. Respiratory syncytial virus infections in pediatric liver transplant recipients. Journal of Infectious Diseases 1992;165(1):166-9.
Purcell 2004
  • Purcell K, Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatric Infectious Disease Journal 2004;23(5):418-23.
Red Book 2009
  • Physician's Desk Reference. Red Book Drug Topics. Montvale, NJ: Thomson Reuters, 2009.
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Roeckl-Wiedmann 2003
  • Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. European Journal of Pediatrics 2003;162(4):237-44.
SIGN 2006
  • Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in Children: A National Clinical Guideline. www.sign.ac.uk/pdf/sign91.pdf (accessed 22 January 2009).
Sigurs 1995
  • Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Björkstén B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995;95(4):500-5.
Sigurs 2000
  • Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. American Journal of Respiratory and Critical Care Medicine 2000;161(5):1501-7.
Sigurs 2005
  • Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. American Journal of Respiratory and Critical Care Medicine 2005;171(2):137-41.
Simoes 2007
  • Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. Journal of Pediatrics 2007;151(1):34-42, 42.e1.
Singleton 2003
  • Singleton R, Dooley L, Bruden D, Raelson S, Butler JC. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatric Infectious Disease Journal 2003;22(6):540-5.
Southern 2007
Speer 2008
  • Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. The Pediatric Infectious Disease Journal 2008;27(6):559-61.
Stein 1999
Tarran 2005
  • Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Lazarowski ER, et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. Journal of Biological Chemistry 2005;280(42):35751-9.
Thompson 2003
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289(2):179-86.
Thorburn 2009
Vicente 2003
  • Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Hospitalization for respiratory syncytial virus in the pediatric population in Spain. Epidemiology and Infection 2003;131(2):867-72.
Wang 1984
  • Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. New England Journal of Medicine 1984;311(26):1653-8.
Wang 2006

References to other published versions of this review

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Robinson 2010
  • Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007743.pub2]
Robinson 2012
Robinson 2013
  • Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD007743.pub4]